OPNT News and Press, Opiant Pharmaceuticals Inc.

Summary Horizon Therapeutics Public Limited Company is a $25 billion biotech that's being acquired by Amgen Inc. The FTC has issued a 2nd request following a letter by Senator Elizabeth Warren. Warren raises a number of important issues but few that pertain specifically to this deal...

Summary Opiant appears on track to be acquired for $20/share and offers various Contingent Value Rights (CVRs) linked to a potential drug launch. The drug helps with opioid reversal after an overdose and has a scheduled FDA review date of May 2023. If certain revenue targets are hit...

CFIUS clearance represents the final required regulatory approval to complete the proposed merger Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023 Indivior and Opiant c...

SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant...

Specialty pharma company Opiant Pharmaceuticals ( NASDAQ: OPNT ) announced that the FDA accepted its New Drug Application (NDA) for nasal opioid overdose therapy OPNT003, granting it the agency’s Priority Review designation. The FDA has issued May 22, 2023, as the target action...

FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for...

Summary I love to get a CVR during a takeover process. This happens a lot when pharma or biotech companies with important unapproved assets get bought. The CVR helps to bridge the gap between the price the seller wants and the buyer wants to pay. They are always uniquely structu...

NEW YORK, NY / ACCESSWIRE / December 11, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: KnowBe4, Inc. (NASDAQ:KNBE)'s sale...

London-based bio-tech company Indivior is hosting a capital markets day in New York, but the company did release some information prior to the all-day event and stated it plans to list on the NASDAQ. It is targeting the spring of 2023 for its listing. The company focuses on addictio...

NEW YORK, NY / ACCESSWIRE / November 24, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Opiant Pharmaceuticals, Inc. (NA...